We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App





Mast Group Launches New ESPLINE SARS-CoV-2 Lateral Flow Antigen Test

By LabMedica International staff writers
Posted on 26 Nov 2020
Mast Group Ltd. More...
(Liverpool, UK) has launched the new ESPLINE SARS-CoV-2 lateral flow antigen test for the detection of COVID-19.

The ESPLINE SARS-CoV-2 is an immunochromographic assay for the detection of SARS-CoV-2 antigen directly from nasopharyngeal swab. The lateral flow test is to be used as an aid in the diagnosis of SARS-CoV-2 infection. ESPLINE SARS-CoV-2 is a cassette-style assay using a simple procedure without any special instruments. As a feature, the test kit utilizes several kinds of antibodies to capture protein insideSARS-CoV-2 and coloring method based on enzyme reaction to detect the antigen-antibody complex.

The test kit shows test result within 30 minutes after the reaction begins (positive results: 10-30 minutes, negative results: 30 minutes). The ESPLINE SARS-CoV-2 lateral flow antigen test has a sensitivity of 80% and specificity of 100%.

Related Links:
Mast Group Ltd.


Gold Member
Multiplex Genetic Analyzer
MassARRAY Dx Analyzer (Europe only)
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.